Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Total Liabilities: 2021-2025

Historic Total Liabilities for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $102.2 million.

  • Krystal Biotech's Total Liabilities rose 5.96% to $102.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.2 million, marking a year-over-year increase of 5.96%. This contributed to the annual value of $109.5 million for FY2024, which is 175.62% up from last year.
  • Krystal Biotech's Total Liabilities amounted to $102.2 million in Q3 2025, which was up 4.57% from $97.7 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Total Liabilities registered a high of $109.5 million during Q4 2024, and its lowest value of $12.4 million during Q1 2021.
  • Over the past 3 years, Krystal Biotech's median Total Liabilities value was $78.8 million (recorded in 2024), while the average stood at $70.5 million.
  • As far as peak fluctuations go, Krystal Biotech's Total Liabilities surged by 452.48% in 2022, and later crashed by 38.11% in 2023.
  • Krystal Biotech's Total Liabilities (Quarterly) stood at $32.7 million in 2021, then rose by 10.70% to $36.2 million in 2022, then rose by 9.65% to $39.7 million in 2023, then spiked by 175.62% to $109.5 million in 2024, then rose by 5.96% to $102.2 million in 2025.
  • Its Total Liabilities was $102.2 million in Q3 2025, compared to $97.7 million in Q2 2025 and $89.7 million in Q1 2025.